Swiftsure International Inc.
Holmes Biopharma: Awarded Contracts Reach $10.5 Million

Holmes Biopharma Inc. / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma: Awarded Contracts Reach $10.5 Million

Scottsdale, Arizona – November 8, 2007 – Holmes Biopharma, Inc. (Berlin
Stock Exchange symbol HHJA, security code A0KDRX) announces that it has
reached $10.5 million USD in awarded contracts for its Phase 1 operation in
Omaha, Nebraska.

The Company is pleased in the dramatic and steady increase of sales
activity from December 2006 through to October 2007. Awarded contracts have
risen from $200,000 to $10.5 million USD in only ten months, a fantastic
accomplishment for any company.

'We are well on our way to meeting our sales target for the first year of
operation, and believe we can double sales in 2008.' stated Dr. Sohail
Khattak, President & CEO Qualia Clinical Service, Inc..

About Holmes:
Holmes Biopharma Inc. and its wholly owned subsidiary, Qualia Clinical
Service, Inc. is a contract research organization focused on providing
integrated and cost effective clinical development services that help the
pharmaceutical industry introduce new drug products rapidly from laboratory
to the market. Holmes is also actively involved in developing new drugs and
drug delivery systems. Currently, clinics operate in Omaha, Nebraska USA,
Toronto, Canada. and Kiev, Ukraine, Eastern Europe. For more information
about the company please visit our website at www.holmesbiopharma.com.


On behalf of the Board of Directors 

John F. Metcalfe, President

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:

John F. Metcalfe, President and CEO  
C/O Holmes Biopharma Inc.
www.holmesbiopharma.com
Tel: 001-800-778-4990 Email: ir@holmesbiopharma.com
8655 East Via De Ventura, G-200, Scottsdale AZ 85258
08.11.2007  Financial News transmitted by DGAP
----------------------------------------------------------------------